Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.31 |
| ▸ | FPR3 | P25089 | 1/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7028322 | 1.00 | PRCP (0.34) | PRCPHTR2CARG1AKT2ADAM17 | |
| SCHEMBL14395328 | 1.00 | PRCP (0.34) | PRCPHTR2CARG1AKT2ADAM17 | |
| SCHEMBL19996549 | 0.79 | PRCP (0.45) | PRCPAKT2 | |
| SCHEMBL5711822 | 0.78 | PRCP (0.53) | PRCPHTR2C | |
| SCHEMBL10681169 | 0.76 | PRCP (0.42) | PRCPAKT2 | |
| SCHEMBL28980916 | 0.75 | HSD17B10 (0.38) | PRCPHTR2CAKT2 | |
| SCHEMBL2146145 | 0.75 | HTR2C (0.52) | HTR2C | |
| SCHEMBL6626467 | 0.75 | PRCP (0.53) | PRCPAKT2 | |
| SCHEMBL2146136 | 0.75 | HTR2C (0.52) | HTR2C | |
| SCHEMBL7765233 | 0.73 | KMT2A (0.49) | PRCPAKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242426-B1 | GAMMA-HYDROXY-2-(FLUOROALKYLAMINOCARBONYL)-1-PIPERAZINEPENTANAMIDES AS HIV PROTEASE INHIBITORS | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20030191121-A1 | Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation | MILLER ROSS A (US) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191121-A1 | Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation | PREP, CTSZ, FIP1L1 | PRCP 33/4885HTR2C 1956/4885ARG1 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.